BioSpace News Archive

Genetown

Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares - Jan. 24, 2018

J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Cowen and Company, LLC acted as joint book-running managers for the offering.

January 24, 2018
·
3 min read
Pharm Country

UroGen Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Full Exercise of Underwriters’ Option

Jefferies LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. Oppenheimer & Co. Inc. acted as lead manager for the offering.

January 24, 2018
·
3 min read
Pharm Country

Insmed Announces Pricing of Public Offering of Convertible Senior Notes

Insmed has granted the underwriters a 30-day option to purchase up to an additional $50 million in aggregate principal amount of the notes, solely to cover over-allotments.

January 24, 2018
·
10 min read
Business

Sanofi: Availability of the Pre-quarterly Results Communication - Jan. 24, 2018

Each quarter, Sanofi prepares this document to assist in the financial modeling of the Group’s quarterly results.

January 24, 2018
·
3 min read
Policy

FDA Has Approved Faron’s Traumakine IND

The FDA has already proposed that Faron can proceed directly to BLA pending positive results from the two on-going Phase III trials

January 24, 2018
·
3 min read
Business

pSivida Corp. Announces Second Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information

Management will host a conference call to review the results at 4:30 p.m. ET on the same day.

January 24, 2018
·
2 min read
Business

Eleven Biotherapeutics Appoints Richard Fitzgerald as Chief Financial Officer

Mr. Fitzgerald had been serving in the role on an interim basis since October 2017.

January 24, 2018
·
5 min read
Policy

Endo Agrees to FDA’s Request to Seek Temporary Litigation Stay

The litigation also seeks the immediate removal of vasopressin from FDA’s Category 1 nominations list to assure that outsourcing facilities do not engage in bulk compounding of vasopressin-containing drug products under Section 503B.

January 24, 2018
·
5 min read
Drug Development

Generon Successfully Concludes First Phase III Clinical Trial of F-627 for Chemotherapy-Induced Neutropenia

Patients treated with F-627 demonstrated significantly reduced duration of severe neutropenia compared to patents in placebo group (P<0.0001).

January 24, 2018
·
3 min read
Drug Development

Glenmark Pharma Presents Preliminary Biomarker Data on GBR 1302, a HER2xCD3 Bispecific Monoclonal Antibody, at the ASCO-SITC Clinical Immuno-Oncology Symposium

Glenmark Pharma today announced a presentation of preliminary biomarker findings from a Phase 1 study of GBR 1302.

January 24, 2018
·
3 min read